Imvotamab

Names

[ Name ]:
Imvotamab

Biological Activity

[Description]:

Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)[1][2][3][4].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

[In Vitro]

Imvotamab (1-10000 pM) 对利妥昔单抗耐药 ramos 细胞具有杀伤作用[5]。 Imvotamab (0.1-1000 pM) 对 standard ramos 细胞具有杀伤作用[5]。 Imvotamab (1-1000 pM) 显著减少了细胞激素释放症候群中 IL-6、IL-2、IFNγ 和 TNFα 的含量[5]。

[In Vivo]

Imvotamab (0.001-10 mg/kg；单剂量) 显著减少了食蟹猴体内的 B 细胞百分比[5]。 Imvotamab (25 mg/kg) 在非人灵长类动物中促进了脾脏和淋巴组织中的 B 细胞耗竭，且没有显著的不良影响[5]。

[References]

[1]. Hernandez G H, et al. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies[J]. Blood, 2022, 140(Supplement 1): 6436-6438.

[2]. Li K, et al. Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile[J]. Blood, 2022, 140(Supplement 1): 6010-6011.

[3]. Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136: 45-46.

[4]. Hart K C, et al. High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing[J]. Cancer Research, 2022, 82(12_Supplement): 4179-4179.

[5]. Baliga R, et al. A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release[J]. Cancer Res, 2020, 80(16 Supplement): 5664-5664.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.